The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by Professor Thomas Foltynie @uclqsion.bsky.social @uclbrainscience.bsky.social https://www.ucl.ac.uk/news/2025/feb/glp-1-drug-shows-little-benefit-people-parkinsons-disease
Comments